Midgard Finance drug data

The extracted weight-loss table for the named drugs, joined to trial design, one row per arm and timepoint. Rows are NOT collapsed to one number per drug. The corpus holds several doses, timepoints and estimands per trial, and picking a single winner per drug would mean choosing between them here, silently and on the caller's behalf. The comparison is theirs to make; this returns the rows and the labels needed to make it correctly.

Extracted adverse-event rates for a named drug or trial, by arm, with the arithmetic that was checked. `drug` is a molecule or a brand (tirzepatide or Zepbound). `ae_type` narrows to a kind of event, every word of it found in the stored type: discontinuation_ae is the share who stopped the drug because of an adverse event (quit over side effects), and the others include discontinuation_ae_gi, nausea, vomiting, diarrhea, constipation, serious_ae, any_ae and death. `available_ae_types` lists the types the named drug or trial holds. `not_published` names the matching trials that hold no rows because their side-effect figures were never published, with what the sponsor did say (REDEFINE 4, the CagriSema and tirzepatide head-to-head). `verification` is carried through verbatim. It is the raw-count recomputation recorded when the row was extracted ("997/2481 active = 40.18%"), and it is what lets a caller see that the percentage was checked against the paper rather than copied from an abstract.

Full record for one drug, with its efficacy figures estimand-tagged and its page URL. Matching goes slug, then exact name or brand, then substring, so "wegovy", "Wegovy HD" and "semaglutide-obesity" all land somewhere sensible without the caller knowing the slug scheme.

The digitised weight-loss curve for a drug: week-by-week points, plus per-dose series. Returned with `endpoint_pct` and its estimand alongside the curve, because the endpoint marker and the last plotted point are different quantities and the curve alone does not say which one a reader is looking at.

One trial's design, by NCT number or by trial key (SURMOUNT-1, scale, redefine-1).

Upcoming and recent readouts, approvals and trial starts across sponsors. Dates are ISO strings where the event has a date and a bare year where the sponsor has only guided to one, so they are compared as strings rather than parsed - "2026" sorts before "2026-07-01", which is the right answer for an event guided to a year.

The latest news the site's hubs print, newest first, with date, headline, source and page. Use it for "what is new" and "latest announcement" questions. It holds the eight newest items of each hub: obesity, Novo Nordisk and Eli Lilly. `company` matches the hub (Novo Nordisk, Eli Lilly) or the drug's sponsor, `drug` a drug or brand in the item or its headline, `query` a word in the headline (MASH, approval). `kind` on a Novo hub item says what it is (clinical, regulatory, corporate, results, competitor: a rival's event that bears on Novo). An event older than a hub's eight newest is not here: say so rather than guess. A headline's efficacy figure is on the estimand the headline names, if any, and is not comparable with one on another.

Search the drug boards by free text and by field. `query` also matches the other indications a molecule is pursuing, from the indications matrix (MASH, CKD, sleep apnea, heart failure, CV outcomes, type 2 diabetes, and their trial names), so "MASH" finds every cardiometabolic drug with a MASH programme and its status. `sponsor` also matches a partner the matrix names (survodutide is licensed from Zealand Pharma to Boehringer Ingelheim). Each result carries its `indications` row, or null for a drug the matrix does not cover (cancer and immunology drugs, and MASH-only drugs, are not in it).